PMID- 22260652
OWN - NLM
STAT- MEDLINE
DCOM- 20120831
LR  - 20161125
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 15
IP  - 3
DP  - 2012
TI  - The cost-effectiveness of celecoxib vs diclofenac in the treatment of 
      osteoarthritis in the UK; an update to the NICE model using data from the CONDOR 
      trial.
PG  - 465-72
LID - 10.3111/13696998.2012.659778 [doi]
AB  - OBJECTIVES: The National Institute for Health and Clinical Excellence (NICE) 
      health economic model for assessing the cost-effectiveness of celecoxib plus a 
      proton pump inhibitor (PPI) compared to diclofenac plus PPI in the treatment of 
      osteoarthritis has been updated using new adverse event (AE) risks from the 
      CONDOR trial. In light of this new information, this study aimed to evaluate the 
      incremental cost-effectiveness ratio (ICER) of celecoxib plus PPI compared to 
      diclofenac plus PPI. METHODS: NICE developed a health economic model as part of 
      their 2008 multiple technology assessment of treatments for osteoarthritis. The 
      model was adapted for this study to update the relative risks of adverse events, 
      using data from the CONDOR trial. RESULTS: Using the AE data from the CLASS trial 
      alone, celecoxib plus PPI has an ICER of  pound9538 per QALY when compared to 
      diclofenac plus PPI. When the AE data from CONDOR alone is used, this ICER 
      decreases to  pound4773 per QALY. Using the pooled data from both trials, celecoxib 
      plus PPI has an ICER of  pound9377 per QALY compared to diclofenac plus PPI. 
      DISCUSSION: The results suggest that when new AE risks are used, celecoxib plus 
      PPI remains a cost-effective treatment for OA when compared to diclofenac plus 
      PPI. However, this analysis is limited by the short time horizon, and additional 
      AEs that have not been considered.
FAU - Brereton, N
AU  - Brereton N
AD  - BresMed Health Solutions, Sheffield, UK. nbrereton@bresmed.co.uk
FAU - Winn, B
AU  - Winn B
FAU - Akehurst, R
AU  - Akehurst R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120214
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - 144O8QL0L1 (Diclofenac)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
MH  - *Advisory Committees
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - Celecoxib
MH  - Cost-Benefit Analysis
MH  - Cyclooxygenase 2 Inhibitors/adverse effects/*economics/therapeutic use
MH  - Diclofenac/adverse effects/*economics/therapeutic use
MH  - Humans
MH  - Middle Aged
MH  - Models, Economic
MH  - Osteoarthritis/*drug therapy
MH  - Pyrazoles/adverse effects/*economics/therapeutic use
MH  - *Randomized Controlled Trials as Topic
MH  - Sulfonamides/adverse effects/*economics/therapeutic use
MH  - United Kingdom
EDAT- 2012/01/21 06:00
MHDA- 2012/09/01 06:00
CRDT- 2012/01/21 06:00
PHST- 2012/01/21 06:00 [entrez]
PHST- 2012/01/21 06:00 [pubmed]
PHST- 2012/09/01 06:00 [medline]
AID - 10.3111/13696998.2012.659778 [doi]
PST - ppublish
SO  - J Med Econ. 2012;15(3):465-72. doi: 10.3111/13696998.2012.659778. Epub 2012 Feb 
      14.